SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Innoviva, Inc. (Last) (First) (Middle) 1350 OLD BAYSHORE HIGHWAY SUITE 400 (Street) BURLINGAME CA 94010 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Armata Pharmaceuticals, Inc. [ ARMP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/10/2023
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Debt convertible into Common Stock(1)(2)(3)(4)(5)	$1.52	01/10/2023		P		$30,000,000		(1)(2)(3)(4)	(1)(2)(3)(4)	Common Stock	19,736,843	$30,000,000(1)(2)(3)(4)	$30,000,000(1)(2)(3)(4)	I(1)(2)(3)(4)	See Footnotes(1)(2)(3)(4)(5)

1. Name and Address of Reporting Person* Innoviva, Inc. (Last) (First) (Middle) 1350 OLD BAYSHORE HIGHWAY SUITE 400 (Street) BURLINGAME CA 94010 (City) (State) (Zip)

1. Name and Address of Reporting Person* Innoviva Strategic Opportunities LLC (Last) (First) (Middle) 1350 OLD BAYSHORE HIGHWAY SUITE 400 (Street) BURLINGAME CA 94010 (City) (State) (Zip)

Explanation of Responses:

1. As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC ("Innoviva Sub"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. ("Innoviva" and, together with Innoviva Sub, the "Reporting Persons") with the Securities and Exchange Commission ("Commission") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the "Issuer") entered into, as borrower, a secured convertible credit and security agreement (the "Credit Agreement") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the "Loan") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024.

2. The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the "Mandatory Conversion") into shares of the Issuer's common stock, $0.01 par value per share ("Common Stock") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event).

3. The Credit Agreement also requires the Issuer to file a registration statement (the "Registration Statement") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the "Optional Conversion"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement.

4. In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87.

5. In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. In 2021, Innoviva designated Jules Haimovitz, a member of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4.

	INNOVIVA, INC. By: /s/ Pavel Raifeld Name: Pavel Raifeld Title: Chief Executive Officer	01/12/2023
	INNOVIVA STRATEGIC OPPORTUNITIES LLC By: Innoviva, Inc., its managing member By: /s/ Pavel Raifeld Name: Pavel Raifeld Title: Chief Executive Officer	01/12/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.